Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend interlude was relaxing enough that you had a chance to catch up with life and take a few deep breaths. Now, of course, what resembles the new routine — Zoom, Skype and the like — has predictably returned. So time to fortify ourselves with a delicious cup of stimulation, and we invite you to join us. After all, the neurons need as much help as they can get, yes? On that note, here are a few tidbits you can wash down. Hope all goes well today, and do stay safe. …

AstraZeneca (AZN) will make as many as 30 million doses of coronavirus vaccine available to the U.K. by September and has committed to delivering 100 million doses this year. And the U.K. will be the first country to get access to the vaccine should it be successful, Bloomberg News writes. The vaccine, which is being developed at the University of Oxford with $79 million of funding, is already being studied in humans and could reach late-stage trials by the middle of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.